We claim:
1. A high-temperature fuel cell, comprising:
a bipolar plate made from CrFe5Y2O31 and having a fuel-gas side;
a nickel layer disposed on said fuel-gas side of said bipolar plate;
a nickel grid spot-welded in an electrically conducting manner onto said nickel layer; and
a solid electrolyte disposed on said nickel grid.
2. The high-temperature fuel cell according to claim 1, wherein said nickel layer is a chemically plated coating on said bipolar plate.
3. The high-temperature fuel cell according to claim 1, wherein said nickel layer is an electroplated coating on said bipolar plate.
4. The high-temperature fuel cell according to claim 1, said nickel layer has a thickness of approximately 20 m.
5. A stack of high-temperature fuel cells, comprising a plurality of connector plates stacked on top of one another and an electrolyte disposed therebetween, each two adjacent said connector plates forming a high-temperature fuel cell according to claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of reducing the risk of developing estrogen-sensitive tumours in a mammal, the estrogen-sensitive tumours being selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, endometriosis, uterine fibroids, benign prostatic hyperplasia and melanoma, the method comprising administering to the mammal a therapeutically effective amount of an estrogenic component selected from the group consisting of:
(a) substances represented by the following formula
in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms;
(b) precursors of the estrogen substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl;
tetrahydropyranyl; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue; and
(c) mixtures of one or more of the aforementioned substances andor precursors.
2. The method according to claim 1, wherein no more than 3 of R1, R2, R3, R4 are hydrogen atoms;
3. The method according to claim 1, wherein 3 of the groups R1, R2, R3 and R4 represent hydrogen atoms.
4. The method according to claim 1, wherein R3 represents a hydroxyl group or an alkoxy group.
5. The method according claim 1, wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 30 days.
6. The method according to claim 1, wherein the method comprises oral administration.
7. The method according to claim 1, wherein the method does not comprise administration of a GnRH composition.
8. The method according to claim 1, wherein the method comprises orally administering to the mammal a therapeutically effective amount of the estrogenic component in combination with an aromatase inhibitor.
9. The method according to claim 1, wherein the estrogenic component is administered in an amount of at least 1 \u03bcg per kg of bodyweight per day.
10. A pharmaceutical composition comprising:
a. at least 0.01 mg of an aromatase inhibitor;
b. at least 0.05 mg of an estrogenic component selected from the group consisting of:
(i) substances represented by the following formula
in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms;
(ii) precursors of the estrogen substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl;
tetrahydropyranyl; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue; and
(iii) mixtures of one or more of the aforementioned substances andor precursors; and
c. pharmaceutically acceptable excipient.
11. The pharmaceutical composition according to claim 10, wherein no more than 3 of R1, R2, R3, R4 are hydrogen atoms.
12. The pharmaceutical composition according to claim 11, wherein 3 of the groups R1, R2, R3 and R4 represent hydrogen atoms.
13. The pharmaceutical composition according to claim 10, wherein R3 represents a hydroxyl group or an alkoxy group.
14. The pharmaceutical composition according to claim 10, wherein the composition comprises aromatase inhibitor in an amount equivalent to an oral dosage of at least 0.05 mg anastrozole.
15. The pharmaceutical composition according to claim 10, wherein the composition is an oral dosage unit.